Autosomal Agammaglobulinemia: Disease-Characteristics Research Report

Executive summary and scope

Autosomal agammaglobulinemia is not one monogenic disease but a heterogeneous group of inherited disorders in which early B-cell development fails because of an autosomal defect. The defining laboratory pattern is profound reduction or absence of circulating B cells, markedly reduced immunoglobulins, and preserved T-cell numbers/function in the classic forms. It phenocopies X-linked agammaglobulinemia (XLA) but lacks a causal BTK variant. Autosomal recessive (AR) disease predominates; uncommon autosomal dominant (AD) syndromes involve genes such as TCF3 and TOP2B. XLA accounts for approximately 85% of congenital agammaglobulinemia, leaving autosomal and genetically unresolved forms as a small minority. AR forms generally present younger and more severely than XLA. (benali2020geneticapproachesfor pages 1-2, mina2021molecularrequirementsfor pages 4-5, cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5)

The strongest recent synthesis is Tangye et al., Journal of Experimental Medicine, published June 2023, DOI 10.1084/jem.20221105. Its abstract states: “The fundamental importance of the role of human B cells in host defense against infectious diseases has been established by the discovery of inborn errors of immunity that disrupt B cell development, differentiation, or function.” (tangye2023inbornerrorsof pages 3-3, tangye2023inbornerrorsof pages 2-3)

Evidence boundary. Autosomal disease is exceptionally rare, and most treatment, outcome, quality-of-life, and infection-management evidence is extrapolated from combined agammaglobulinemia or primary-antibody-deficiency cohorts dominated by XLA. Subtype-specific claims below are identified where possible. PMID values were not exposed in the retrieved full-text metadata; DOI URLs are therefore supplied rather than inventing PMID identifiers.

1. Disease information

Definition and classification

Autosomal agammaglobulinemia is an inborn error of immunity/predominantly antibody deficiency caused by germline variants that interrupt B-cell lineage development, usually at the pro-B–to–pre-B transition. The operational phenotype is:

• severe hypogammaglobulinemia or agammaglobulinemia;
• absent or profoundly reduced peripheral CD19+/CD20+ B cells, commonly below 0.5–2% of lymphocytes;
• recurrent, severe, or unusual bacterial infections, usually beginning in infancy after maternally transferred IgG wanes;
• no pathogenic BTK variant;
• usually normal T-cell counts in isolated pre-BCR-pathway defects. (benali2020geneticapproachesfor pages 1-2, benali2020geneticapproachesfor pages 4-6)

Identifiers and synonyms

• Preferred label: autosomal agammaglobulinemia.
• Common synonyms: autosomal recessive agammaglobulinemia; non-X-linked agammaglobulinemia; congenital autosomal agammaglobulinemia; agammaglobulinemia due to a specified gene defect; autosomal B-cell deficiency.
• ICD-10-CM: D80.0, hereditary hypogammaglobulinemia, is the closest umbrella code; coding should preserve the molecular subtype in accompanying text.
• ICD-11: classified under predominantly antibody deficiencies/inborn errors of immunity; a subtype-specific code should be verified in the local release.
• MeSH: Agammaglobulinemia.
• MONDO/OMIM/Orphanet: individual molecular forms have separate entries; the retrieved evidence did not verify a single authoritative MONDO or Orphanet identifier covering every autosomal form. A knowledge base should therefore model “autosomal agammaglobulinemia” as an umbrella concept linked to gene-defined child diseases, rather than assign an unverified single identifier.

The evidence is primarily aggregated disease-level literature, reviews, and small molecular cohorts—not individual EHR records. The most informative primary cohort comprised six affected people from four consanguineous North-African families. (benali2020geneticapproachesfor pages 1-2)

2. Etiology, risks, protective factors, and gene–environment relationships

Causal factors

The primary cause is a germline genetic defect affecting one of four functional modules:

1. Pre-B-cell receptor assembly: IGHM, IGLL1, CD79A, CD79B.
2. Pre-BCR/BCR signal transduction: BLNK, PIK3R1, and in some classifications PIK3CD.
3. Transcription, DNA topology, or ionic homeostasis: TCF3, TOP2B, SLC39A7.
4. Cellular metabolic control: FNIP1, involving AMPK–mTOR homeostasis. (mina2021molecularrequirementsfor pages 4-5, tangye2023inbornerrorsof pages 3-3, tangye2023inbornerrorsof pages 2-3, tangye2023inbornerrorsof pages 6-7)

A 2020 human study found homozygous IGHM frameshifts p.Val378Alafs1 and p.Ile184Serfs21 in three patients and homozygous CD79A p.Trp66 in two sisters. All had undetectable or very low immunoglobulins, B cells below 0.5%, and normal T-cell counts. A sixth agammaglobulinemic patient had homozygous RAG2 p.Glu407, illustrating that a broader combined-immunodeficiency differential may mimic the phenotype. (benali2020geneticapproachesfor pages 1-2, benali2020geneticapproachesfor pages 4-6)

Risk factors

• Family history and consanguinity: the major ascertainable risks for AR disease. The North-African cohort explicitly arose from consanguineous families. (benali2020geneticapproachesfor pages 1-2)
• Sex: unlike XLA, autosomal disease affects all sexes. A female infant or child with absent B cells particularly warrants evaluation for an autosomal defect.
• De novo dominant variation: relevant to AD TCF3 or TOP2B disease.
• Age: age does not cause disease, but clinical infection susceptibility rises as maternal IgG falls during infancy.

Protective factors

No validated protective allele, diet, lifestyle, or environmental exposure prevents the underlying developmental defect. Clinically protective measures include early diagnosis, immunoglobulin replacement, rapid antimicrobial treatment, selected prophylactic antibiotics, respiratory surveillance, and avoidance of live vaccines. (benali2020geneticapproachesfor pages 1-2, cardenasmorales2022agammaglobulinemiafromxlinked pages 8-10)

Gene–environment interaction

The genotype establishes profound humoral immune failure; environmental exposure determines which infections occur and how much secondary organ damage accumulates. Repeated airway infections cause a feed-forward cycle of epithelial injury, impaired mucociliary clearance, bronchiectasis, and further infection. There is no evidence that toxins, smoking, diet, pollution, or occupational exposure initiates the Mendelian disease, although smoke and respiratory pollutants plausibly worsen acquired lung damage. Infectious agents are complications, not causes.

3. Phenotypes

Children with IGHM deficiency presented at a reported mean of 11 months, compared with 35 months in BTK-related XLA, and had severe infections including enteroviral disease and Pseudomonas sepsis. Approximately 30% developed neutropenia. (cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5)

Quality of life is impaired by infection burden, chronic airway disease, school/work disruption, repeated infusions, venous access, and anxiety about infection. However, no validated EQ-5D, SF-36, or PROMIS estimates specific to autosomal agammaglobulinemia were identified.

4. Genetic and molecular information

The principal molecular subtypes are summarized below.

Table: This table summarizes the autosomal genetic subtypes of agammaglobulinemia supported by the retrieved evidence, highlighting inheritance, developmental mechanisms, and representative human findings. It is useful for distinguishing the umbrella diagnosis from its heterogeneous molecular causes.

Variant interpretation

• Origin: causal variants are germline; somatic disease is not the recognized mechanism.
• Common classes: nonsense, frameshift, splice-disrupting, missense/hypomorphic, and occasionally larger deletions.
• Functional effects: most AR variants are loss-of-function; dominant TOP2B and some TCF3/E47 variants act through dominant-negative effects. (cardenasmorales2022agammaglobulinemiafromxlinked pages 12-13, benali2020geneticapproachesfor pages 4-6)
• Population frequency: pathogenic alleles are expected to be rare; no defensible gene-wide carrier frequency or exact gnomAD frequency can be assigned without variant-specific database queries.
• ACMG classification: each variant requires case-level ACMG/AMP evaluation incorporating segregation, population frequency, predicted loss of function, functional evidence, and phenotype. “Gene associated with disease” does not make every rare variant pathogenic.
• Penetrance/expressivity: severe biallelic null pre-BCR defects are generally highly penetrant, but hypomorphic variants can be leaky. Expressivity is variable, as illustrated by complete CD79A versus hypomorphic CD79B developmental blocks and syndromic TOP2B disease. (cardenasmorales2022agammaglobulinemiafromxlinked pages 12-13)

No consistently validated modifier genes, disease-specific methylation signature, histone abnormality, recurrent aneuploidy, or characteristic chromosomal rearrangement was identified. Copy-number variants remain diagnostically relevant when sequencing is negative.

5. Environmental, lifestyle, and infectious information

No non-genetic exposure is known to cause autosomal agammaglobulinemia. Environmental and lifestyle factors primarily modify complications:

• respiratory smoke and pollution should be minimized because chronic airway damage can compound infection risk;
• safe food and water practices reduce gastrointestinal pathogen exposure;
• prompt evaluation of fever and respiratory symptoms is important;
• household infection control is relevant during outbreaks.

Typical infectious susceptibility includes recurrent bacterial respiratory infections, enteric infections, and severe or chronic enterovirus infection. IGHM deficiency has been associated with enteroviral infection and Pseudomonas sepsis. Serology is unreliable because patients cannot produce normal antibody responses; pathogen diagnosis should preferentially use culture, antigen detection, or nucleic-acid amplification. (cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5)

6. Mechanism and pathophysiology

Core causal chain

Pathogenic germline variant → defective pre-BCR assembly/signaling or B-lineage transcription/metabolism → developmental arrest in bone marrow → profound loss of immature and mature B cells → absent plasma-cell and antibody output → impaired neutralization, opsonization, complement recruitment, and mucosal defense → recurrent infection → cumulative tissue injury, especially bronchiectasis and gastrointestinal disease. (mina2021molecularrequirementsfor pages 4-5, tangye2023inbornerrorsof pages 3-3, tangye2023inbornerrorsof pages 2-3)

Upstream mechanisms

1. Pre-BCR assembly: productive μ-heavy-chain expression (IGHM) must combine with surrogate light-chain components, including λ5 (IGLL1), and signal through Igα/Igβ (CD79A/CD79B). Disruption prevents the proliferative and survival checkpoint from pro-B to pre-B cell. (mina2021molecularrequirementsfor pages 4-5, tangye2023inbornerrorsof pages 2-3)
2. Signal transduction: BLNK coordinates signaling involving BTK and PI3K. PIK3R1/PIK3CD encode regulatory/catalytic PI3K subunits that produce PIP3 after receptor ligation. Failure suppresses developmental survival and expansion. (tangye2023inbornerrorsof pages 3-3, tangye2023inbornerrorsof pages 2-3)
3. Transcription/development: TCF3/E47 acts earlier, around common lymphoid progenitor–to–pro-B commitment; dominant-negative variants may produce BCR-negative B cells. (mina2021molecularrequirementsfor pages 4-5, cardenasmorales2022agammaglobulinemiafromxlinked pages 12-13)
4. DNA topology: dominant-negative TOP2B variants impair proliferation and survival of conventional B-2 cells, blocking development and humoral responses. (mina2021molecularrequirementsfor pages 4-5)
5. Ion/metabolic homeostasis: SLC39A7 demonstrates a requirement for divalent-cation homeostasis in lymphocyte signaling. FNIP1 deficiency perturbs energy homeostasis, increasing mTOR and AMPK activity; marrow shows excess pro-B/pre-BI cells and reduced pre-BII/immature B cells. Six patients from five families had B-cell deficiency, agammaglobulinemia, and recurrent respiratory infection. (mina2021molecularrequirementsfor pages 4-5, tangye2023inbornerrorsof pages 6-7)

Downstream mechanisms

The downstream injury is predominantly infection-mediated rather than autoimmune or intrinsically degenerative. Deficient antibody production impairs opsonophagocytosis of encapsulated bacteria and viral neutralization. Repeated pulmonary infections damage airway epithelium, producing chronic suppuration and bronchiectasis. Enteroviral persistence can produce severe neurologic or systemic disease.

Ontology suggestions

• GO biological process: B-cell differentiation (GO:0030183); B-cell activation (GO:0042113); B-cell receptor signaling pathway (GO:0050853); immune response (GO:0006955); immunoglobulin production (GO:0002377); phosphatidylinositol 3-kinase signaling; regulation of mTOR signaling.
• Cell Ontology: hematopoietic stem cell; common lymphoid progenitor; pro-B cell; pre-B cell; immature B cell; mature B cell; plasma cell. Exact CL identifiers should be resolved against the current Cell Ontology release.
• GO cellular component: pre-B-cell receptor complex; B-cell receptor complex; plasma membrane; cytosol; nucleus for TCF3/TOP2B.

No clinically validated autosomal-specific transcriptomic, proteomic, metabolomic, lipidomic, spatial-transcriptomic, or multi-omics diagnostic signature was found. Marrow flow cytometry and functional genetic studies remain more directly informative.

7. Anatomical structures affected

Primary site

The primary anatomical lesion is in bone marrow B-cell development.

• Suggested UBERON: bone marrow (UBERON:0002371).
• Affected cells: pro-B, pre-B, immature B, and consequently circulating mature B cells and plasma cells.
• Primary compartments: pre-BCR/BCR at the plasma membrane; cytosolic signaling complexes; nucleus for TCF3 and TOP2B.

Secondary sites

• Respiratory system: middle ear, paranasal sinuses, bronchi, and lungs; recurrent infection may lead to bronchiectasis.
• Gastrointestinal tract: recurrent infection and chronic diarrhea.
• Central nervous system: secondary involvement in severe or chronic enteroviral infection.
• Lymphoid organs: small or poorly developed tonsils/lymph nodes may reflect absent B-cell follicles.
• TOP2B-related disease: craniofacial, limb, and urogenital structures may be congenitally abnormal. Ten affected people from five kindreds were summarized in the retrieved review. (mina2021molecularrequirementsfor pages 4-5)

Lateralization is not characteristic.

8. Temporal development

The molecular defect is congenital, but symptoms usually emerge when maternally transferred IgG declines during the first year of life. AR forms tend to present earlier and more severely than XLA; IGHM deficiency had a mean reported presentation age of 11 months. (cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5)

The untreated course is chronic and punctuated by acute infections. There are no formal disease stages, but a useful clinical model is:

1. Pre-symptomatic congenital phase: absent/low B-cell output; KREC may already be undetectable.
2. Early infectious phase: recurrent otitis, sinusitis, pneumonia, diarrhea, sepsis, or neutropenia.
3. Established chronic disease: recurrent infection despite care, chronic sinus or lung disease.
4. Complicated disease: bronchiectasis, chronic enteroviral infection, organ damage, or severe sepsis.

There is no spontaneous remission of a true null developmental defect. Apparent improvement may reflect immunoglobulin replacement, resolution of infection-associated neutropenia, or a hypomorphic/leaky genotype. The critical intervention window is before recurrent infections produce irreversible lung damage.

9. Inheritance and population

Epidemiology

Reliable prevalence or incidence per 100,000 is unavailable for autosomal agammaglobulinemia as an umbrella category. XLA represents about 85% of congenital agammaglobulinemia; IGHM deficiency alone has been estimated at approximately 5% of all cases. Other subtypes are generally represented by individual families or very small series. (benali2020geneticapproachesfor pages 1-2, cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5)

Inheritance

• AR: IGHM, IGLL1, CD79A, CD79B, BLNK, SLC39A7, FNIP1, and some PIK3R1/TCF3 presentations.
• AD: selected TCF3 and TOP2B disorders; dominant disease may be de novo.
• Recurrence risk: for a confirmed AR disorder, each full sibling has a 25% affected, 50% carrier, and 25% non-carrier probability. For an affected heterozygous AD parent, transmission risk is 50%, subject to penetrance.
• Consanguinity: materially increases AR disease probability and has facilitated discovery in North-African and other consanguineous families. (benali2020geneticapproachesfor pages 1-2)
• Sex ratio: expected to be approximately equal for nonsyndromic autosomal disease, although tiny cohorts preclude a stable estimate.
• Anticipation: not expected.
• Germline mosaicism: theoretically possible, particularly after an apparently de novo variant, but no subtype-specific rate is established.
• Founder effects/carrier frequency: may exist for individual variants, but no generalizable frequency was found.

10. Diagnostics

Clinical and laboratory evaluation

Suspect the disorder in any child—especially a girl, a child of consanguineous parents, or a patient without a BTK defect—with recurrent severe infection, extremely low immunoglobulins, and absent B cells.

Recommended evaluation:

1. Quantitative serum IgG, IgA, and IgM, interpreted using age-specific ranges.
2. CBC and differential, particularly for neutropenia.
3. Flow cytometry for CD3, CD4, CD8, CD19/CD20, and NK cells. In classic agammaglobulinemia, B cells are commonly below 2%; the molecular cohort reported below 0.5% with normal T-cell numbers. (benali2020geneticapproachesfor pages 1-2, benali2020geneticapproachesfor pages 4-6)
4. Vaccine-specific antibody titers are generally absent, but intentional live-vaccine challenge is contraindicated and additional vaccination solely to prove failure is usually unnecessary in profound agammaglobulinemia.
5. Culture/PCR rather than antibody serology for suspected infection.
6. Pulmonary assessment—oxygen saturation, chest imaging, and pulmonary function when age-appropriate—if recurrent pneumonia, chronic cough, or suspected bronchiectasis is present.
7. Bone-marrow immunophenotyping is not routinely required but can localize the developmental block in unresolved cases.

Genetic testing strategy

• Begin with an inborn-errors-of-immunity/agammaglobulinemia panel containing at least BTK, IGHM, IGLL1, CD79A, CD79B, BLNK, PIK3R1, PIK3CD, SLC39A7, TCF3, TOP2B, FNIP1, and relevant phenocopy genes such as RAG1/RAG2.
• In a classic male phenotype, BTK testing remains essential even if the referral label says “autosomal.”
• Use deletion/duplication analysis because sequence-only assays can miss exon or multiexon copy-number changes.
• If the panel is negative or the phenotype is syndromic, proceed to trio WES or WGS. The 2020 cohort concluded that sequential testing was expensive and slow, whereas WES produced a more efficient definitive diagnosis in genetically heterogeneous families. (benali2020geneticapproachesfor pages 1-2)
• Confirm candidate variants by orthogonal sequencing, segregation, population-frequency review, and functional studies when classification remains uncertain.
• CMA is reasonable for syndromic disease or suspected copy-number change; routine karyotype, FISH, mitochondrial sequencing, and repeat-expansion testing are not first-line.

Newborn screening

Kappa-deleting recombination excision circles (KREC) may be low or undetectable from birth and remain low in autosomal agammaglobulinemia. Combined TREC/KREC screening can identify severe B-cell lymphopenia before infection, but KREC screening is not universally implemented and may miss leaky defects. Its potential value is earlier immunology referral, avoidance of live vaccines, and timely Ig replacement. (cardenasmorales2022agammaglobulinemiafromxlinked pages 8-10)

Differential diagnosis

• XLA due to BTK variants.
• Severe combined immunodeficiency or leaky SCID, including RAG1/RAG2 disease.
• Transient hypogammaglobulinemia of infancy—B cells are generally present.
• Common variable immunodeficiency—usually later onset with B cells present.
• Hyper-IgM syndromes—IgM is normal/high rather than universally absent.
• Secondary hypogammaglobulinemia from anti-CD20 therapy, nephrotic/protein-losing disease, malignancy, or immunosuppressive therapy.
• Thymoma-associated immunodeficiency in adults.

11. Outcome and prognosis

Without treatment, severe bacterial infection, sepsis, chronic enteroviral disease, and progressive lung injury confer substantial morbidity and mortality. Immunoglobulin replacement prevents many infections and improves survival, but it does not reverse established bronchiectasis or congenital syndromic abnormalities. (benali2020geneticapproachesfor pages 1-2)

Major morbidity includes recurrent hospitalization, chronic sinus and lung disease, bronchiectasis, gastrointestinal infection, neurologic enterovirus complications, and treatment burden. Prognosis is best with diagnosis before irreversible organ damage, adequate Ig exposure, adherence, rapid treatment of breakthrough infections, and specialist respiratory care.

No robust autosomal-only 5-year survival, life-expectancy, mortality, disability, or quality-of-life statistic was identified. Genotype may influence prognosis: IGHM disease is often early and severe; hypomorphic CD79B/IGLL1 defects may be milder; TOP2B prognosis includes nonimmune congenital anomalies. These genotype–phenotype relationships remain based on small cohorts and should not be used deterministically. (mina2021molecularrequirementsfor pages 4-5, cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5, cardenasmorales2022agammaglobulinemiafromxlinked pages 12-13)

12. Treatment

Standard therapy

Lifelong immunoglobulin replacement is the treatment of choice for non-transplanted patients. IVIG and SCIG provide passive IgG, reduce serious bacterial infection, and improve survival. The dose and interval should be individualized to infection control, pharmacokinetics, weight, bronchiectasis, and adverse effects rather than a universal trough alone. (benali2020geneticapproachesfor pages 1-2, cardenasmorales2022agammaglobulinemiafromxlinked pages 8-10)

Suggested NCIt concepts include Immunoglobulin Replacement Therapy, Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Antibiotic Therapy, and Hematopoietic Stem Cell Transplantation; exact NCIt codes should be resolved against the current NCIt release.

Antimicrobial and supportive care

• Treat suspected bacterial infection promptly; obtain cultures where feasible.
• Consider prophylactic antibiotics for recurrent infection despite optimized Ig replacement or established bronchiectasis.
• Use airway-clearance therapy and respiratory specialist management for bronchiectasis.
• Monitor CBC, immunoglobulin exposure, infection frequency, pulmonary function, and liver/renal status as clinically indicated.
• Adverse effects of Ig therapy include infusion reactions, headache/aseptic meningitis, thrombosis, hemolysis, and renal injury; SCIG generally reduces systemic reactions but causes local-site reactions.

Advanced and experimental therapy

Hematopoietic stem-cell transplantation is not routine first-line therapy for isolated agammaglobulinemia because lifelong Ig replacement is effective and transplantation has substantial risk. It may be considered for selected severe syndromic/combined defects, uncontrollable complications, or a genotype for which immune reconstitution is established. No approved gene therapy, CRISPR therapy, RNA therapy, or genotype-specific small molecule exists for the autosomal agammaglobulinemia umbrella.

A ClinicalTrials.gov search retrieved IVIG/SCIG studies enrolling broad primary hypo-/agammaglobulinemia populations, including NCT00138697, NCT00161993, and NCT00520494, but no clearly autosomal-subtype-specific interventional trial. Consequently, product studies support Ig replacement generally but cannot establish gene-specific response rates.

Pharmacogenomics

No validated CPIC/PharmGKB genotype-guided dosing rule specific to these genes and immunoglobulin replacement was identified.

13. Prevention

Primary prevention

The disease cannot be prevented after conception through lifestyle change. Reproductive options after identifying the familial variant include genetic counseling, carrier testing, prenatal diagnosis, and preimplantation genetic testing. Cascade testing is appropriate for at-risk relatives.

Secondary prevention

• Identify affected newborns through family-based testing or TREC/KREC programs where available.
• Begin immunology follow-up and Ig replacement before severe infection when diagnostic criteria are met.
• Avoid delays caused by repeated treatment of infections without immune evaluation.

Tertiary prevention

• Maintain adequate Ig replacement and adherence.
• Use antimicrobial prophylaxis selectively.
• Perform respiratory surveillance and airway clearance.
• Ensure dental, nutritional, and gastrointestinal care.
• Prefer inactivated vaccines when vaccination is indicated; responses may be minimal but household immunization provides indirect protection.
• Avoid live attenuated vaccines in the affected person, particularly oral poliovirus and other live viral products, unless a specialist has documented sufficient immunity in an atypical leaky phenotype.
• Vaccinate close contacts according to public-health guidance while considering precautions around transmissible live vaccines.

No diet, supplement, exercise program, or environmental intervention substitutes for Ig replacement.

14. Other species and natural disease

No well-established naturally occurring veterinary disorder exactly equivalent to the full human autosomal-agammaglobulinemia umbrella was identified in the retrieved evidence. Therefore, no defensible breed, VBO identifier, animal incidence, or zoonotic implication can be assigned.

Orthologs of the implicated genes are evolutionarily conserved across vertebrates, and the pre-BCR checkpoint is conserved in mammals. The disorder is inherited and not transmissible or zoonotic. Any veterinary annotation should be made at the individual gene/ortholog level through OMIA and NCBI Gene rather than inferred from the human umbrella label.

15. Model organisms and experimental systems

The best retrieved primary model evidence concerns TOP2B. Broderick et al., Nature Communications, published August 2019, DOI 10.1038/s41467-019-11570-6, used Saccharomyces cerevisiae and knock-in/knockout mice. The abstract reports that patient variants “have a dominant negative effect on enzyme function, resulting in defective proliferation, survival of B-2 cells, causing a block in B cell development, and impair humoral function in response to immunization.” This provides cross-system functional evidence connecting variant, enzyme dysfunction, cellular phenotype, and impaired antibody response. (mina2021molecularrequirementsfor pages 4-5)

Model categories and uses

• Mouse knockout/conditional knockout: localizes B-lineage developmental checkpoints and measures marrow subsets, peripheral B cells, serum immunoglobulins, and immunization responses.
• Knock-in/humanized alleles: tests dominant-negative or hypomorphic patient variants.
• Yeast: useful for TOP2B enzyme-function studies but cannot model adaptive immunity.
• Patient-derived cells: flow cytometry, immunoblotting, signaling assays, and rescue experiments can validate candidate variants.
• iPSC/organoid systems: potentially useful but no clinically mature autosomal-agammaglobulinemia platform was identified.

Limitations

Murine B-cell development is informative but not identical to human development; redundancy and lineage distribution differ. Complete knockout models may overstate the severity of human hypomorphic alleles. Yeast models assess conserved enzymatic function but not B-cell-specific physiology.

Recent developments and expert interpretation

1. 2023 mechanistic consolidation: Tangye et al. integrated pre-BCR, PI3K, transcriptional, ionic, and metabolic defects into a human B-cell-development framework, emphasizing that rare patients function as natural experiments defining essential pathways. (tangye2023inbornerrorsof pages 3-3, tangye2023inbornerrorsof pages 2-3, tangye2023inbornerrorsof pages 6-7)
2. FNIP1 as a metabolic B-cell-development disorder: six patients from five families showed agammaglobulinemia with a marrow shift from later pre-B/immature cells toward earlier pro-B/pre-BI stages and abnormal AMPK–mTOR activity. (tangye2023inbornerrorsof pages 6-7)
3. Broadening phenotype recognition: recent work increasingly recognizes leaky B-cell lymphopenia and hypogammaglobulinemia rather than only complete absence of B cells. This supports early genomic testing and argues against requiring a textbook phenotype before sequencing.
4. Screening innovation: KREC measurement can detect severe B-cell lymphopenia at birth, although implementation and sensitivity for partial defects remain unresolved. (cardenasmorales2022agammaglobulinemiafromxlinked pages 8-10)
5. Expert consensus: early molecular diagnosis matters because it confirms inheritance, directs family counseling, distinguishes isolated antibody deficiency from combined immunodeficiency, and may alter consideration of transplantation. The 2020 cohort demonstrates the practical superiority of WES over serial single-gene testing in consanguineous, genetically heterogeneous families. (benali2020geneticapproachesfor pages 1-2)

Knowledge-base conclusions

Autosomal agammaglobulinemia should be represented as a Mendelian disease family, not as a single gene–disease pair. Its invariant biological axis is failure of early B-cell development and antibody production, but inheritance, developmental checkpoint, syndromic involvement, and severity depend on the causal gene and allele. The most robust annotations are absent/reduced B cells, severe hypogammaglobulinemia, recurrent respiratory infection, early childhood onset, pre-BCR/BCR-pathway dysfunction, and benefit from lifelong immunoglobulin replacement. Autosomal-specific prevalence, survival, quality-of-life, environmental interaction, omics biomarkers, and treatment-response statistics remain major evidence gaps.

References

1. (benali2020geneticapproachesfor pages 1-2): Meriem Ben-Ali, Nadia Kechout, Najla Mekki, Jing Yang, Koon Wing Chan, Abdelhamid Barakat, Zahra Aadam, Jouda Gamara, Lamia Gargouri, Beya Largueche, Nabil BelHadj-Hmida, Amel Nedri, Houcine Ben Ameur, Fethi Mellouli, Rachida Boukari, Mohamed Bejaoui, Aziz Bousfiha, Imen Ben-Mustapha, Yu-Lung Lau, and Mohamed-Ridha Barbouche. Genetic approaches for definitive diagnosis of agammaglobulinemia in consanguineous families. Journal of Clinical Immunology, 40:96-104, Nov 2020. URL: https://doi.org/10.1007/s10875-019-00706-4, doi:10.1007/s10875-019-00706-4. This article has 13 citations and is from a domain leading peer-reviewed journal.

2. (mina2021molecularrequirementsfor pages 4-5): Erika Della Mina, Antoine Guérin, and Stuart G. Tangye. Molecular requirements for human lymphopoiesis as defined by inborn errors of immunity. Stem Cells, 39:389-402, Jan 2021. URL: https://doi.org/10.1002/stem.3327, doi:10.1002/stem.3327. This article has 4 citations and is from a highest quality peer-reviewed journal.

3. (cardenasmorales2022agammaglobulinemiafromxlinked pages 4-5): Melissa Cardenas-Morales and Vivian P. Hernandez-Trujillo. Agammaglobulinemia: from x-linked to autosomal forms of disease. Clinical Reviews in Allergy & Immunology, 63:22-35, Jul 2022. URL: https://doi.org/10.1007/s12016-021-08870-5, doi:10.1007/s12016-021-08870-5. This article has 86 citations and is from a peer-reviewed journal.

4. (tangye2023inbornerrorsof pages 3-3): Stuart G. Tangye, Tina Nguyen, Elissa K. Deenick, Vanessa L. Bryant, and Cindy S. Ma. Inborn errors of human b cell development, differentiation, and function. The Journal of Experimental Medicine, Jun 2023. URL: https://doi.org/10.1084/jem.20221105, doi:10.1084/jem.20221105. This article has 72 citations.

5. (tangye2023inbornerrorsof pages 2-3): Stuart G. Tangye, Tina Nguyen, Elissa K. Deenick, Vanessa L. Bryant, and Cindy S. Ma. Inborn errors of human b cell development, differentiation, and function. The Journal of Experimental Medicine, Jun 2023. URL: https://doi.org/10.1084/jem.20221105, doi:10.1084/jem.20221105. This article has 72 citations.

6. (benali2020geneticapproachesfor pages 4-6): Meriem Ben-Ali, Nadia Kechout, Najla Mekki, Jing Yang, Koon Wing Chan, Abdelhamid Barakat, Zahra Aadam, Jouda Gamara, Lamia Gargouri, Beya Largueche, Nabil BelHadj-Hmida, Amel Nedri, Houcine Ben Ameur, Fethi Mellouli, Rachida Boukari, Mohamed Bejaoui, Aziz Bousfiha, Imen Ben-Mustapha, Yu-Lung Lau, and Mohamed-Ridha Barbouche. Genetic approaches for definitive diagnosis of agammaglobulinemia in consanguineous families. Journal of Clinical Immunology, 40:96-104, Nov 2020. URL: https://doi.org/10.1007/s10875-019-00706-4, doi:10.1007/s10875-019-00706-4. This article has 13 citations and is from a domain leading peer-reviewed journal.

7. (tangye2023inbornerrorsof pages 6-7): Stuart G. Tangye, Tina Nguyen, Elissa K. Deenick, Vanessa L. Bryant, and Cindy S. Ma. Inborn errors of human b cell development, differentiation, and function. The Journal of Experimental Medicine, Jun 2023. URL: https://doi.org/10.1084/jem.20221105, doi:10.1084/jem.20221105. This article has 72 citations.

8. (cardenasmorales2022agammaglobulinemiafromxlinked pages 8-10): Melissa Cardenas-Morales and Vivian P. Hernandez-Trujillo. Agammaglobulinemia: from x-linked to autosomal forms of disease. Clinical Reviews in Allergy & Immunology, 63:22-35, Jul 2022. URL: https://doi.org/10.1007/s12016-021-08870-5, doi:10.1007/s12016-021-08870-5. This article has 86 citations and is from a peer-reviewed journal.

9. (cardenasmorales2022agammaglobulinemiafromxlinked pages 12-13): Melissa Cardenas-Morales and Vivian P. Hernandez-Trujillo. Agammaglobulinemia: from x-linked to autosomal forms of disease. Clinical Reviews in Allergy & Immunology, 63:22-35, Jul 2022. URL: https://doi.org/10.1007/s12016-021-08870-5, doi:10.1007/s12016-021-08870-5. This article has 86 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00